Rhode Island is currently home to 495 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Providence, Warwick, East Providence and Johnston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Biliary Atresia Research Network Northeast
NCT06184971
Recruiting
This is a multi-center retrospective chart review to compile a data repository of the management and outcomes of children with biliary atresia. Overall, investigators aim to evaluate which specific factors contribute to improved patient outcomes, to help guide potential improvements in patient care and resource utilization.
Gender:
ALL
Ages:
12 years and below
Trial Updated:
03/06/2025
Locations: Rhode Island Hospital/Hasbro Children's Hospital, Providence, Rhode Island
Conditions: Biliary Atresia
Register for Updates
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
NCT06084481
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Each cohort receives ABBV-400 alone (monotherapy) followed by a safety follow-up per... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Lifespan Cancer Institute at Rhode Island Hospital /ID# 257693, Providence, Rhode Island
Conditions: Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
Register for Updates
Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL
NCT03666000
Recruiting
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL and r/r B-cell NHL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Lifespan Cancer Institute at Rhode Island Hospital, Providence, Rhode Island
Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Register for Updates
Brain and Behavior Influences on Obesity Development From Infancy Through Childhood
NCT06861868
Recruiting
The investigators project, RESONATE, aims to investigate why some children develop obesity. To do this it uses data on eating and eating-related behaviors, genetic and environmental factors, and brain structure and function. This data is collected in a sub-sample of RESONANCE, a large study of families of children from infancy through childhood. The results will lay foundations for the development of early interventions to prevent or treat obesity.
Gender:
ALL
Ages:
Between 7 years and 12 years
Trial Updated:
03/05/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Obesity and Overweight
Register for Updates
Ultrasound Guided Serratus Anterior Plane Block in ED Patients with Rib Fractures
NCT06299137
Recruiting
The goal of this clinical trial is to test the effectiveness of the Serratus Anterior Plane Block in patients with rib fractures. The main questions it aims to answer are: * Determine if UG-SAPB results in an improved pain, incentive spirometry, and cough ability (PIC) score when compared to usual care over the first five hours. * Evaluate if UG-SAPB results in fewer opioid medications administered when compared to usual care over the first 24 hours. Participants will undergo the Serratus Ante... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Rib Fractures, Pain Acute, Regional Anesthesia, Opioid Use
Register for Updates
Tagraxofusp and Azaxitadine with or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
NCT05442216
Recruiting
A treatment cycle is 28 days for Cycle 1 and Cycle 2. Tagraxofusp will be administered at 12 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 5 consecutive days (or 5 doses over a period not to exceed 10 days if postponement is required to allow for toxicity resolution). Subjects with a marrow CR (See the protocol) after Cycle 2 will continue Tagraxofusp for Cycles 3 to 12 (up to 1 year of treatment) at 12 mcg/kg IV for 5 consecutive days every 28 days. In subjects without a marrow CR aft... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Lifespan Health System Rhode Island Hospital, Providence, Rhode Island
Conditions: Acute Myeloid Leukemia
Register for Updates
Addressing Weight Bias Internalization to Improve Adolescent Weight Management Outcomes: Randomized Pilot Trial
NCT06864208
Recruiting
Weight stigma and weight bias internalization (WBI) are common among adolescents at higher weight statuses. WBI is associated with negative physical and mental health outcomes. The current study aims to test an intervention for weight stigma and WBI combined with an evidence-based adolescent weight management program. Eligible adolescents (13-17) will be assigned by chance to one of two groups: 1) a 4-week intervention focused on weight stigma and WBI followed by a 16-week behavioral weight mana... Read More
Gender:
ALL
Ages:
Between 13 years and 17 years
Trial Updated:
03/03/2025
Locations: The Miriam Hospital, Providence, Rhode Island
Conditions: Weight, Body Weight, Weight Bias, Weight Stigma, Physiological Stress, Biological Markers of Stress, Biological Markers of Inflammation, Eating Behaviors
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Providence, Rhode Island
Conditions: Neoplasms
Register for Updates
Development of a Lifestyle Physical Activity Intervention to Reduce Risk for Perinatal Cannabis Use
NCT05528380
Recruiting
This study will recruit 20 women who are high risk for prenatal cannabis use for a 12-week program of using the tracker and receiving a Lifestyle Physical Activity program. The primary outcomes will be self reported percent days of cannabis use and physical activity. Secondary outcomes include self -reported measures of depression and anxiety symptoms, adaptive coping, and self-efficacy for cannabis abstinence.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Butler Hospital, Providence, Rhode Island
Conditions: Pregnancy, Cannabis
Register for Updates
Feasibility & Acceptability of App-based Cognitive Behavioral Therapy for Postpartum Depression Prevention
NCT06365645
Recruiting
Postpartum depression (PPD) affects up 10-15% of mothers overall, but the rate of PPD can be as high as 25% among mothers with personal or obstetric risk factors. The Mothers \& Babies Program (MB) is a cognitive behavioral therapy (CBT)-based program that has been shown to prevent PPD among high-risk mothers without a prior history of depression. MB has been so consistently effective that the United States Preventive Services Task Force recommends this program be given to high-risk pregnant pat... Read More
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
02/26/2025
Locations: Women & Infants Hospital of Rhode Island, Providence, Rhode Island
Conditions: Postpartum Depression, Postpartum Anxiety, Stress
Register for Updates
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931
Recruiting
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/26/2025
Locations: Research Site, Providence, Rhode Island
Conditions: Transthyretin Amyloid Cardiomyopathy
Register for Updates
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
NCT04427384
Recruiting
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2025
Locations: Brown University Health, Providence, Rhode Island
Conditions: Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
Register for Updates